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Abstract 
ZSTK474 is a potent phosphoinositide 3-kinase (PI3K) inhibitor that reduces cell proliferation via 
G1-arrest. However, there is little information on the susceptibility of this anticancer drug to 
resistance conferred by the multidrug pumps P-glycoprotein (ABCB1) and ABCG2. We have 
demonstrated that ZSTK474 generated cytotoxicity in cells over-expressing either pump with 
potency similar to that in drug sensitive cells. In addition, the co-administration of ZSTK474 with 
the cytotoxic anti-cancer drugs vinblastine and mitoxantrone caused a potentiated cytotoxic effect in 
both drug sensitive and efflux pump expressing cells. These observations suggest that ZSTK474 is 
unaffected by the presence of multidrug efflux pumps and may circumvent their activities. Indeed, 
ZSTK474 increased the cellular accumulation of calcein-AM and mitoxantrone in cells expressing 
ABCB1 and ABCG2, respectively. ZSTK474 treatment also resulted in reduced expression of both 
efflux pumps in multidrug resistant cancer cells. Measurement of ABCB1 or ABCG2 mRNA levels 
demonstrated that the reduction was not due to altered transcription. Similarly, inhibitor studies 
showed that the proteasomal degradation pathway for ABCB1 and the lysosomal route for ABCG2 
degradation were unaffected by ZSTK474. Thus the mechanism underlying reduced ABCB1 and 
ABCG2 levels caused by ZSTK474 was due to a reduction in overall protein synthesis; a process 
influenced by the PI3K pathway. In summary, ZSTK474 is not susceptible to efflux by the 
resistance mediators ABCB1 and ABCG2. Moreover, it inhibits the drug transport function of the 
pumps and leads to a reduction in their cellular expression levels. Our observations demonstrate that 
ZSTK474 is a powerful anticancer drug. 
 
Keywords: 
P-glycoprotein; ABCG2; ZSTK474; multidrug resistance; membrane transport; cancer 
chemotherapy 
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Chemical Compounds: 
ZSTK474 (PubChem CID: 11647372); vinblastine (PubChem CID: 241903); mitoxantrone 
(PubChem CID: 4212); calcein-AM (PubChem CID: 4126474); nicardipine (PubChem CID: 4474); 
fumetrimorgen C (PubChem CID: 403923) 
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1. Introduction 
Chemotherapy of cancer continues to move away from geno- and cytotoxic compounds due to 
severe side-effects and a high susceptibility to resistance mechanisms. Components of aberrant cell 
signalling pathways involved in growth and proliferation provide numerous new targets. A prime 
candidate is the PI3K/Akt/mTOR pathway, which is up-regulated or activated in almost 50% of 
tumours and is involved in cell proliferation, survival and nutrient metabolism (Bauer et al., 2015; 
Kong and Yamori, 2008). Pharmacological inhibition of this pathway reduces cell proliferation; 
thereby providing the basis for potential anti-cancer activity. 
Several compounds targeting the PI3K/Akt/mTOR pathway have been developed as specific 
inhibitors of the phosphoinositide 3-kinase (PI3K) enzyme family (Kong and Yamori, 2008). 
Phosphorylation of phosphatidylinositol-bisphosphate (PIP2) generates the powerful second 
messenger phosphatidyl-3,4,5-trisphosphate (PIP3), which triggers the signalling cascade involved 
in cell growth and survival (Engelman et al., 2006). The PI3K family comprises four classes of 
enzyme, each with multiple isoforms that differ in substrate specificity, tissue distribution and the 
downstream effectors (Vanhaesebroeck et al., 2001).  
Structural data for the PI3Kg isoform has revealed chemical features for drug binding and thereby 
facilitated the development of new isoform-specific inhibitors (Walker et al., 1999). One of these is 
the triazine derivative ZSTK474, which has been shown to inhibit the PI3K pathway in cancer cell 
lines and in vivo tumour models (Yaguchi et al., 2006). ZSTK474 inhibits cell proliferation by 
causing arrest of the cell cycle in the G1-phase, but without induction of apoptosis (Dan et al., 2012; 
Wang et al., 2016c). ZSTK474 acts specifically on PI3K, with negligible effects on the DNA-PK 
and mTOR kinases (Kong and Yamori, 2008). Data gathered through a combination of 
pharmacological and molecular modelling approaches suggest that ZSTK474 binds to PI3K within 
the ATP binding pocket of the enzyme and competes at greater potency than LY294002 with 
nucleotide (Yaguchi et al., 2006). 
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A number of PI3K inhibitors are in clinical development and the mTOR inhibitor Everolimus has 
FDA approval for the treatment of renal cell carcinoma and pancreatic tumours (2016; Yao et al., 
2016), and the selective PI3Kd isoform inhibitor Idealisib has been approved as a single agent to 
treat small lymphocytic lymphoma and non-Hodgkin lymphoma (Nair and Cheson, 2016). Whilst 
these are encouraging signs for the utility of PI3K inhibitors as anticancer drugs, the spectre of 
resistance is ever present. A “front-line” factor in drug resistance is the over-expression of 
multidrug efflux pumps to mediate the ATP-dependent efflux of chemotherapy agents to levels 
below that required to elicit apoptosis. The efflux pumps, P-glycoprotein (P-gp, ABCB1), ABCG2 
and ABCC1 (Mrp1) are from the ATP Binding Cassette (ABC) family and their over-expression is 
associated with a resistant phenotype and poor chemotherapeutic outcome (McHugh and Callaghan, 
2008; Modok et al., 2006). This manuscript will deal specifically with ABCB1 and ABCG2, which 
recognise an astonishing number of substrates.  
The aim of this investigation was to assess the potency and efficacy of ZSTK474 in cell lines that 
overexpress ABCB1 and ABCG2 to ascertain its susceptibility to these key resistance mediators.  
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2. Materials & Methods 
2.1 Materials 
Trypsin (Trypsin-EDTA solution), adenosine triphosphate (ATP), propidium iodide, vinblastine 
sulfate salt, mitoxantrone dihydrochloride, flavopiridol hydrochloride hydrate, doxorubicin 
hydrochloride, verapamil hydrochloride, nicardipine hydrochloride, fumitremorgin C (FTC) 
bortezomib, concanamycin A and calcein-acetoxy methyl ester (calcein-AM) were purchased from 
Sigma-Aldrich (Castle Hill, NSW). Penicillin-streptomycin solution (10000 U/ml penicillin 10000 
µg/ml streptomycin) and MTT (3-(4,5-dimethylthiazol-2-yl-)-2,5-diphenyltetrazolium 
bromide) were purchased from ThermoFisher Scientific (Scoresby, Vic). DMEM 
medium was purchased from Lonza (Vic, Australia) and foetal bovine serum (FBS) from Biological 
Bovogen Ltd (Vic, Australia). 
 
2.2 Tissue Culture 
The drug-sensitive human breast adenocarcinoma cell line MCF7
WT
 (ATCC
®
 HTB-22
™
) was 
purchased from the American Type Culture Collection (Rockville, MD). The flavopiridol-selected 
ABCG2-expressing derivative cell line MCF7
FLV1000
 was obtained from Dr. S Bates (National 
Cancer Institute, Bethesda, MD) (Robey et al., 2001) and the doxorubicin-selected ABCB1-
expressing variant NCI/ADR
Res
 cell line was obtained from Dr K Cowan (National Cancer Institute, 
Bethesda, MD) (Mehta et al., 2002). All cell lines were grown as monolayer cultures in DMEM 
medium supplemented with 10% FBS, penicillin (10000 U/ml) and streptomycin (10000 mg/ml) at 
37°C with 5% CO2. To maintain selection pressure for resistance, every third passage of 
NCI/ADR
Res
 and MCF7
FLV1000
 cells were supplemented with doxorubicin (3μM) or flavopiridol 
(0.5nM) respectively. All cells were maintained up to a maximum of 20 passages of sub-culture. 
 
2.3 Cell cytotoxicity assays 
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Cytotoxicity assays were performed as previously described (Debono et al., 2014). Cells were 
seeded in 96-well plates at a density of 1.5 x 10
3
 cells per well in 100µl medium. Cells were 
allowed to attach to for 24 h at 37°C and 5% CO2. ZSTK474, anticancer drugs and pump inhibitors 
were added from a 2X stock solution in medium (100µl) to produce a final concentration range of 
10
-12
 to 10
-4 
M. The solvent (DMSO) concentration in the wells was kept to 0.2 % (v/v). For 
combination cytotoxicity assays, cells were incubated with drugs as described above either in the 
presence of absence of ZSTK474 (0.1-3µM). Drugs and cells were incubated at 37
o
C with 5% CO2 
for 6 days at which point the control wells (i.e. DMSO treated) had reached confluence. 
The viability of cells following drug treatment was assessed using a standard MTT assay 
(Mosmann, 1983). Briefly, following the 6 day incubation period, 20µl of a 5mg/ml MTT solution 
(PBS) was added to each well, and the plates were incubated for 4 h at 37°C. Medium was aspirated 
and the formazan crystals dissolved in 150µl DMSO. The absorbance in each well (λ=570 nm) was 
measured using an iMARK 96-well plate reader and the absorbance in the control wells was 
assigned a value of 100%. The cytotoxic potency (IC50) of each compound was determined from 
plots of the percentage of viable cells as a function of concentration. The data was fitted by a 
sigmoidal dose-response curve using GraphPad Prism® Software v6 (CA, USA). 
The nature of interaction between drugs co-administered in cytotoxicity assays was evaluated by 
Combination Indices (CI) that were calculated using the Lowe’s Additivity Model as described 
(Chou, 2006);  
 ! #$%& =  $'()*)1
+ d-()*)2
 
where d1 and d2 are the concentrations of drug needed respectively to inhibit x% of cells when used 
as a combination, (Dx)1 is the concentration of drug 1 required to inhibit x% of cells, (Dx)2 is the 
concentration of drug 2 needed to inhibit x% of cells.  
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For the purpose of this study, the combination indices were calculated using concentrations 
interpolated where the x% cells affected was 50 (IC50) and 75 (IC75) for the mitoxantrone/ZSTK474 
combination and vinblastine/ZSTK474 combination respectively. A CI value = 1 indicates an 
additive effect, CI<1 indicates synergy and CI>1 indicates antagonism. It was not possible to 
calculate combination values with 1 and 3μM ZSTK474 combinations where the combination 
resulted in a cell viability of less than 20%. 
 
2.4 The purification and functional assessment of ABCB1  
ABCB1 was expressed in Trichoplusia ni (High-Five) cells following infection with recombinant 
baculovirus containing the specific mutant isoform as previously described (Taylor et al., 2001). 
Following infection, cells were harvested by centrifugation and the pellet stored at -80
o
C. Crude 
membranes were prepared from the cells using differential ultracentrifugation following cell 
disruption by nitrogen cavitation as previously described (Taylor et al., 2001) and stored at -80
o
C. 
ABCB1 was purified using immobilised metal affinity chromatography (IMAC) in a gravity based 
system, according to previously published methods with some modifications (Crowley et al., 2009; 
Taylor et al., 2001). The primary difference pertained to the solubilisation conditions. In the present 
investigation, crude membranes (30-100mg) were suspended (5mg/ml protein) in solubilisation 
buffer supplemented with a 0.4% (w/v) lipid mixture (4:1 ratio of E coli extract:cholesterol) and 2% 
(w/v) dodecyl-b-D-maltoside (DDM).  
Functional assessment of ABCB1 was achieved by measuring its ATPase activity based on the rate 
of inorganic phosphate liberation by ABCB1 containing proteoliposomes using a modified 
colorimetric assay (Chifflet et al., 1988; Crowley et al., 2009). In order to investigate the 
stimulation of ATP hydrolysis, the activity was measured as a function of added drug concentration. 
Proteoliposomes (0.1-0.5 mg) were incubated with ATP (2 mM) and various drug concentrations 
(10
-9
 to 10
-4 
M) for 40 min at 37
o
C in 96-well plates. Once the colour-forming reaction was 
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complete, the absorbance at l=750nm was measured for all samples using an iMark Microplate 
reader. The amount of phosphate liberated was determined from extrapolation of absorbance to a 
standard curve of inorganic phosphate (0-20nmol Pi). In all cases the activity was expressed as 
moles of Pi liberated per unit time for a unit of purified ABCB1. The potency (EC50) and extent of 
stimulation of ATPase activity (v) were estimated by non-linear regression of the general dose-
response relationship to plots of activity as a function of drug concentration ([D]):  . = ./0/3/45 +
6.7/045 − ./0/3/459 61 + 1065;<'>(?@ABC[D])99E , where vinitial is the activity in the absence of drug and 
vfinal is the maximal activity observed. 
 
2.5 The calcein-AM accumulation assay in intact cells 
The calcein-AM assay to measure the transport function of ABCB1 was based on a previously 
published method (Homolya et al., 1993). MCF7
WT
 and NCI/ADR
Res
 cells were seeded into 96-well 
tissue culture plates at a density of 2 x 10
3
 cells per well in 100µl and allowed to adhere for 2 days 
at 37°C with 5% CO2. Following incubation, medium was aspirated and cells were washed with 
PBS and re-suspended in 100µl Hank’s Buffered Salt Solution (HBSS). Test compounds (100µl) 
were added at a 2X final concentration in HBSS from an original stock solution of 50mM in 
DMSO. The final solvent (DMSO) concentration in the wells did not exceed 1% (v/v). Calcein-AM 
was added from a 100X HBBS stock to give a final concentration of 1µM. Following the addition 
of calcein-AM, plates were immediately read on a Tecan M1000 PRO plate reader using ‘i 
control
TM
 1-10’ software. The plate was heated in the reader to 37°C and the fluorescence measured 
at an excitation λ=488nm and an emission λ=515nm. Each well was read 16 times in different 
locations to give an averaged fluorescence value and plates were read every minute for 10 minutes. 
The intracellular calcein accumulation (i.e. fluorescence intensity) was plotted as a function of time 
and analysed by linear regression using GraphPad Prism® Software v6. The slope of each line was 
used to determine the rate of calcein accumulation and plotted as a function of calcein-AM 
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concentration. These secondary plots were fitted with a hyperbolic curve using GraphPad Prism
®
 
Software v6 in order to calculate the modulator potency (MP50). The MP50 is defined as the 
concentration to achieve a half-maximal calcein accumulation rate. 
 
2.6 The flow cytometric assay for mitoxantrone accumulation 
Mitoxantrone transport in whole cells by ABCG2 was measured using flow cytometry as previously 
described (Robey et al., 2001). MCF7
WT
 and MCF7
FLV1000
 cells were detached from flasks using 
2mM EDTA and centrifuged at 1500g for 5 min, the pellet was re-suspended in PBS and re-
centrifuged. The final pellet was re-suspended in HBBS in polypropylene tubes at a density of 10
6
 
cells/ml. Cells were incubated in (i) HBSS alone, (ii) HBSS with 3µM mitoxantrone or (iii) HBSS 
in the presence of 5µM mitoxantrone in combination with ZSTK474 (1-100mM) for 1h at 37°C on a 
Stuart SB2 Rotator. Stock solutions of all compounds were prepared in DMSO and the final 
concentration of DMSO did not exceed 1% (v/v), which was determined not to affect mitoxantrone 
accumulation (Mahringer et al., 2009). Cells were centrifuged twice at 2000g for 8 minutes at 4
o
C 
using an Allegra X-12R centrifuge, re-suspended in 500µl ice-cold HBSS solution and transferred 
to cluster tubes. The centrifugation step was repeated, supernatant removed and 100µl of HBSS was 
added to the pellet. A BD Scientific LSR-II Flow Cytometer with a red 633 nm laser was used to 
detect mitoxantrone fluorescence and doublet discrimination was achieved by gating forward-
scatter versus side-scatter. Dead cells were excluded using propidium iodide (PI) staining (1µg/ml) 
detected using the blue 488 nm laser. The PI was added immediately prior to flow cytometry 
analysis. A minimum of ten thousand events were collected per sample and the data was processed 
using FlowJo Software (OR, USA). Data was represented as a histogram showing mean 
intracellular mitoxantrone accumulation in the absence or presence of test compound using 
GraphPad Prism® Software v6.  
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2.7 Protein levels in MCF7
WT
, MCF7
FLV1000
 and NCI/ADR
Res
 cell lines 
Cells were seeded in sterile flat-bottomed 6-well tissue culture plates at 5 x 10
4
 cells per well and 
allowed to attach to the surface for 24 h at 37°C 5% CO2. Following 24 h incubation, a “time zero” 
(or untreated) sample was obtained by aspirating medium from one well, washing with PBS and 
lysing with 1% (w/v) SDS. The test compound, at concentrations indicated in the figure legends, 
was added to the remaining five wells. All drugs were prepared from a 50mM DMSO stock solution 
and the final DMSO concentration did not exceed 1% (v/v). Lysates were prepared from treated 
cells every day for 4 days following drug addition and a final sample was taken 6 days after 
treatment. The cell lysates were stored at -20°C until use. 
Cell lysates were sheared with a fine gauge needle and the total protein concentration of each 
sample was determined using the Detergent Compatible BioRad assay using BSA as a standard. 
Samples of lysate were subjected to SDS-PAGE and transferred to Amersham
TM 
Protran
TM
 
Nitrocellulose Membranes (GE Healthcare Lifesciences, NSW, Australia). The mouse monoclonal 
C219 antibody (Sapphire Bioscience) was used to specifically detect ABCB1 and mouse 
monoclonal BXP-21 antibody (ThermoFisher, Vic, Australia) was used to detect ABCG2. A 
secondary antibody, Amersham™ ECL sheep anti-mouse IgG peroxidase-linked whole antibody 
(GE Healthcare, NSW, Australia), was used to detect bound antibody using chemi-luminescence 
with the Amersham
TM 
ECL Western Blotting Detection Kit (GE Healthcare, NSW, Australia). 
Immuno-reactive protein bands were visualised on the GelDoc Vilber Fusion SL Chemi-
luminescence System. 
Normalisation of the 8% SDS-PAGE gels was achieved quantitatively by loading 9mg of total 
cellular protein in each lane. This strategy of equi-loading based on protein amount obviates the 
potential for erroneous loading with house-keeping genes due to the myriad cellular effects of drug 
treatments used in this investigation (Farmer et al., 1983; Gorr and Vogel, 2015). 
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2.8 Quantitative measurement of ABCB1 and ABCG2 mRNA levels 
NCI/ADR
Res
 & MCF7
FLV1000
 cells were seeded at a density of 10
5
 per well in duplicate and left to 
attach overnight at 37
o
C incubator with 5% CO2. Cells were treated with ZSTK474 (1μM) or 
solvent (DMSO) control for a total of 4 days, with samples collected every 24 h. Following 
incubation, the cells were washed in sterile PBS and total RNA extracted using the NucleoSpin® 
RNA extraction kit (MACHEREY-NAGEL) according to the manufacturer’s protocol. RNA 
concentration and purity was determined using a Nanodrop ND-1000 spectrophotometer (Thermo 
Fisher). Preparations of RNA were treated with a DNAse (1U, 30min, 37
o
C) to remove any 
contaminating DNA. RNA (1μg) was reverse transcribed for 1h at 50
o
C using the Superscript III 
Kit (Invitrogen, Life Technologies) using random hexamers (Promega) and the cDNA was stored at 
-80
o
C until further use. 
Primers for target (ABCB1 & ABCG2) and the housekeeping gene GAPDH were designed using 
the NCBI primer blast database (http://www.ncbi.nlm.nih.gov/tools/primer-blast). Primers, where 
possible, spanned an exon-exon boundary region with primer size kept restricted to 18-22 bases 
with predicted amplicon sizes of 70 to 150bp. The melting temperature range was 58 to 62
o
C and 
GC content was maintained at 20-60%. The primer sequences are shown in Table 1 and were 
purchased from Geneworks (Hindmarsh, Australia). Primers were re-suspended in nuclease free 
water and stored at -20
0
C. 
Cellular ABCB1 and ABCG2 mRNA levels were measured using qRT-PCR in 96-well plates. The 
reaction mixture (20μl) comprised of cDNA template, a final concentration of 300nM forward and 
reverse primers, and Fast SYBR Green Master Mix (Applied Biosystems). Samples were run on the 
Applied Biosystems StepOne Real-Time PCR system with 40 cycles of denaturation, annealing and 
extension. The relative expression of the target gene (ABCB1 and ABCG2) was calculated relative 
to GAPDH using the comparative (ΔΔCt) method. 
 
13 
 
2.9 Quantitative measurement of protein synthesis – the effects of ZSTK474 
MCF7
WT
, NCI/ADR
Res
 and MCF7
FLV1000
 cells were seeded into black (clear bottom) 96 well plates 
at a density of 2.5 x 10
4
 cells per well and left to attach overnight in a 37
0
C incubator with 5% CO2. 
After 24 h the cells were treated with either (a) ZSTK474 (1-3mM) for 48 h, or, (b) cyclohexamide 
(100μg/ml) pre-incubated with the cells for one hour. The effects of drug treatment on total cellular 
protein synthesis were determined using the Protein Synthesis Assay Kit purchased from Cayman 
Chemicals (Michigan, USA). The rate of protein synthesis, compared to a no treatment control, was 
measured using a TECAN M100PRO plate reader to record fluorescence according to the 
manufacturer’s protocol. The relative percentage of protein synthesis was calculated using the 
equation: % HI!% JK!ℎ%JJ =  M NOP ;7 3QR43RS TR55NOP ;7 U03QR43RS TR55V × 100. 
 
2.10 Data analysis 
All curve-fitting and statistical analyses of data were carried out using GraphPad Prism® Software 
v6. The Student’s t test was used for statistical analyses of two groups and for comparison of three 
or more groups, a one-way analysis of variance (ANOVA) using the Dunnett’s post-hoc test was 
used to compare values. P-values of <0.05 were considered statistically significant. 
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3. Results 
3.1 Anti-proliferative activity of ZSTK474 in human cancer cell lines expressing ABCB1 & 
ABCG2 
MCF7
WT
, MCF7
FLV1000
 and NCI/ADR
Res
 cell lines were incubated in the presence of ZSTK474 (10
-
12
 to 10
-4
M) for a period of six days and the percentage of live cells remaining was measured (Fig. 
1). In the parental MCF7
WT
 cell line, the potency of ZSTK474 was defined as IC50 = 0.13±0.02mM 
(n=7) and the number of live cells was <5% at 100mM. ZSTK474 also produced growth inhibition 
of the ABCG2-expressing MCF7
FLV1000
 cells with a potency (IC50 = 0.19±0.05mM, n=7) that was 
not significantly different to the MCF7 cells. In contrast, the potency of ZSTK474 in NCI/ADR
Res
 
cells, which over-express ABCB1, was reduced to IC50 = 1.70±0.31mM (n=7). This 13-fold 
reduction in ZSTK474 potency was statistically significant (P<0.05) but modest in comparison to 
the degree of resistance observed for vinblastine (see below).  
 
3.2 Effects of ZSTK474 in combination with vinblastine on growth inhibition 
The cytotoxicity of vinblastine was measured in the presence of ZSTK474 (0.1 to 3mM) in both 
MCF7
WT
 (Fig. 2a) and NCI/ADR
Res
 (Fig. 2c) cell lines to assess the possibility of a potentiated 
effect with the two drugs. The cytotoxic potency for vinblastine in MCF7
WT
 cells was characterised 
by IC50 = 0.20±0.07nM and the addition of ZSTK474 generated a downward shift in the initial 
plateau level of the cytotoxicity profile (Fig. 2a). In the presence of 0.1µM ZSTK474, the 
cytotoxicity of vinblastine displayed a lower initial plateau (54±12% live cells) but no change in 
potency (IC50 = 0.16±0.07nM). At higher ZSTK474 concentrations, the reduction in the initial 
plateau level was even greater with only 17±9% remaining at 3mM. 
The cytotoxicity of vinblastine in NCI/ADR
Res
 cells was characterised by an IC50 = 181±80nM, 
which is 905-fold lower than in MCF7
WT
 cells. Co-addition of ZSTK474 (0.3mM) to NCI/ADR
Res
 
cells caused the apparent potency of vinblastine to increase three-fold, to an IC50 value of 63±19nM 
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(Fig. 2c). The potency was further increased (IC50 = 19±8nM) at the highest ZSTK474 
concentration (3mM), which was 9-fold lower than observed with vinblastine alone. The co-addition 
of ZSTK474 also caused a downward shift in the initial plateau of the dose-response curves. For 
example, the initial plateau at 0.1µM ZSTK474 was maintained at 96±5% live cells and at 3µM this 
was reduced to 69±10%. Clearly, the reduction in the initial plateau was not as pronounced as 
observed in the MCF7
WT
 cells. However, the increase in the apparent vinblastine potency was only 
observed in the resistant NCI/ADR
Res
 cells. 
To ascertain whether the enhanced response was an additive or synergistic interaction, the data were 
evaluated using combination index (CI) analysis. The CI was determined at each concentration of 
ZSTK474 co-administered with vinblastine and the values are shown in Fig. 3(a-b). An effect level 
that produced a 75% reduction in live cells was selected for analysis. The 75% level was chosen due 
to the effect of ZSTK474 on the initial plateau level. The CI values (for 0.1 and 0.3µM ZSTK474) 
in the MCF7
WT
 cells were not significantly different from a value of 1.0 based on analysis of the 
95% confidence interval, which is suggestive of an additive effect. The large reduction in the initial 
plateau level at higher concentrations precluded determination of a CI value. In contrast, the CI 
values determined in the NCI/ADR
Res
 cells at each ZSTK474 concentration were significantly 
lower than the isobole (dotted lines Fig. 3). This indicates that the combination of vinblastine and 
ZSTK474 exerts a synergistic effect, specifically in the ABCB1 expressing NCI/ADR
Res
 cells. 
 
3.3 Effects of ZSTK474 in combination with mitoxantrone on growth inhibition 
Interaction between ZSTK4747 and the anticancer drug mitoxantrone was also investigated in 
MCF7
WT
 and the ABCG2-expressing MCF7
FLV1000
 cell lines (Fig. 2 (b,d)). The potency of 
mitoxantrone in drug sensitive MCF7
WT
 cells was characterised by an IC50 of 21±6nM in the 
absence of PI3K inhibitor (Fig. 2b). The apparent mitoxantrone potency was increased by the 
addition of 0.1mM (IC50 = 8.9±2.3nM) and 0.3mM (IC50 = 4.1±0.9nM) ZSTK474; the latter 
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represents a statistically significant (P<0.05) increase from the control value. The initial plateau 
level for mitoxantrone in the presence of 0.1µM ZSTK474 was reduced to 76±12% live cells and 
further reduced to 51±18% at 0.3µM. Higher ZSTK474 concentrations resulted in less than 25% 
live MCF7
WT
 cells, thereby preventing the assignment of an accurate IC50-value.  
The MCF7
FLV1000
 cells displayed 420-fold resistance to mitoxantrone as shown by the significant 
reduction in potency (IC50 = 8777±380nM) (Fig. 2d) compared to the MCF7
WT
 cells (IC50 = 
21±6nM) (Fig. 2b). In the presence of 0.3mM ZSTK474, the potency of mitoxantrone was increased 
9-fold (IC50 = 959±426nM). At higher concentrations of ZSTK474 resulted in the reduction of the 
live cell population to <25% of the original level, similar to that observed in MCF7
WT
 cells. 
The interaction between mitoxantrone and ZSTK474 was assessed using CI analysis as shown in 
Fig. 3 (c-d). The CI values at 0.3µM were not significantly different from the isobole (dotted line; 
CI=1.0) and indicate an additive effect of the two drugs. At the lowest concentration of ZSTK474 
(0.1µM) there was clear evidence of a synergistic interaction, although this occurred in both cell 
lines and was therefore independent of ABCG2. Unfortunately, the extent of reduction in the initial 
plateau level at ZSTK474 concentrations of 1-3µM prevented assignment of a CI value in either cell 
line. 
 
3.4 The effects of ZSTK474 on the drug transport and ATP hydrolysis functions of ABCB1  
The ability of ZSTK474 to alter the transport activity of ABCB1 was investigated with the calcein-
AM accumulation assay (Homolya et al., 1993). Calcein-AM and various concentrations of 
ZSTK474 (or nicardipine) were added to MCF7
WT
 and NCI/ADR
Res
 cells and the fluorescence 
intensity measured for ten minutes. 
As expected (Homolya et al., 1993), the addition of either ZSTK474, or nicardipine, failed to cause 
any alteration in the rate of calcein-AM accumulation in the MCF7
WT
 cell line. The rates of 
fluorescence accumulation in NCI/ADR
Res
 cells were plotted as a function of drug concentration as 
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shown for nicardipine (Fig. 4a). The data was fitted by a hyperbolic function to enable estimation of 
the maximal rate of fluorescence increase (DFMAX) and the modulator potency (MP50) to achieve 
this increase. The DFMAX in the presence of nicardipine was 110±19 r.f.u/min (n=11) with a potency 
defined as MP50 = 2.5±0.6mM. ZSTK474 also caused a significant increase in fluorescent signal in 
NCI/ADR
Res
 cells as shown in Fig. 4b. The DFMAX was 20±4 r.f.u/min (n=5) in the presence of 
ZSTK474 and the potency to achieve this rate was MP50 = 1.7±0.5mM. Therefore, ZSTK474 is able 
to modulate the transport function of ABCB1 in NCI/ADR
Res
 cells in a manner similar to 
nicardipine, which suggests a direct interaction between the drug and ABCB1.  
The effects of ZSTK474 on the activity of purified, reconstituted ABCB1 were used to ascertain 
whether there was a direct drug-protein interaction. The ability to stimulate (or inhibit) ATP 
hydrolysis by ABCB1 is a standard measure to indicate interaction with the transporter. As shown 
in Fig. 5, ZSTK474 caused a concentration dependent increase in the rate of ATP hydrolysis by 
ABCB1. The basal ATPase activity was VMIN = 239±69 nmol Pi/min/mg and this was stimulated 
4.5±0.9-fold by ZSTK474 to a maximal activity of 831±177 nmol Pi/min/mg. The potency of 
ZSTK474 to stimulate ATP hydrolysis was defined with an EC50 value of 7.6±1.7mM. Nicardipine 
also stimulated the basal activity (VMIN = 98±45 nmol Pi/min/mg) by 5.3±0.7-fold to a maximal 
activity of VMAX = 591±99 nmol Pi/min/mg. Furthermore, nicardipine stimulated ATP hydrolysis 
by ABCB1 with a similar potency (EC50 = 6.5±1.8mM) to ZSTK474, which is in agreement with 
previously published values (Crowley et al., 2009). 
Together, these data indicate that ZSTK474 modulates the transport function of ABCB1 in a similar 
manner to nicardipine. Moreover, this modulation occurs via a direct interaction with the transporter 
based on its ability to stimulate ATP hydrolysis by ABCB1. 
 
3.5 The effects of ZSTK474 on mitoxantrone accumulation in ABCG2 expressing cells 
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The ability of ZSTK474 to modulate the function of ABCG2 was also investigated given the 
overlap in substrate specificity with ABCB1. The ABCG2 substrate mitoxantrone is intrinsically 
fluorescent and a flow cytometry assay was used to measure its steady-state accumulation in 
MCF7
WT
 and MCF7
FLV1000
 cells.  
Fig. 6a shows representative data for mitoxantrone accumulation of in both cell lines. In MCF7
WT
 
cells mitoxantrone accumulation (3.3x10
4
 r.f.u) was 2.6-fold greater than that observed in the drug-
resistant MCF7
FLV1000
 cells (1.25x10
4
 r.f.u). Furthermore, the addition of the ABCG2 inhibitor FTC 
(10mM) to MCF7
FLV1000
 cells resulted in a 2.3-fold increase in mitoxantrone accumulation (2.9x10
4
 
r.f.u). In contrast, FTC addition to MCF7
WT
 cells did not result in any appreciable change in 
fluorescence (3.5x10
4
 r.f.u) (data not shown for clarity).  
Fig. 6b shows the effects of ZSTK474 on the extent of mitoxantrone accumulation in both MCF7
WT
 
and MCF7
FLV1000
 cell lines. In the absence of ZSTK474, MCF7
WT
 cells (39,368±6,744 r.f.u) 
accumulated 4.1-fold more mitoxantrone than the MCF7
FLV1000
 cells (9,476±1,680 r.f.u). The 
addition of ZSTK474 did not alter mitoxantrone accumulation in MCF7
WT
 cells. In contrast, 
ZSTK474 produced a concentration dependent increase in mitoxantrone accumulation, with a 2.2-
fold increase at 100mM (21,2976±3,550 r.f.u) in MCF7
FLV1000
 cells. This compares similarly to the 
2.4-fold increase in mitoxantrone accumulation produced by the ABCG2 inhibitor FTC (50mM), 
which reached 22,989±1,451 r.f.u (data not shown). The data demonstrate that ZSTK474 is able to 
modulate substrate transport by ABCG2 to a similar extent as FTC.  
 
3.6 The effects of ZSTK474 on ABCB1 expression in cancer cell lines 
Data described in preceding sections demonstrated that ZSTK474 could directly modulate the 
transport activity of ABCB1 and ABCG2. However, ZSTK474 modulates many cellular functions 
controlled by the PI3K/Akt pathway and may therefore have additional influences on ABCB1 and 
ABCG2 expression.  
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ABCB1 expression levels in lysates from NCI/ADR
Res
 cells showed a gradual increase in the first 
2-3 days, before reaching a plateau (Fig. 7a). In the presence of ZSTK474 (1mM), the cellular levels 
of ABCB1 were unaffected in the first two days. However, in subsequent days the expression of 
ABCB1 decreased. The expression blots were repeated multiple times (n>3) and ZSTK474 
reproducibly caused a reduction in ABCB1 levels (6233±2232 vs 13941±2729 pixels). In contrast 
to ZSTK474, the addition of nicardipine (1mM) had no effect on ABCB1 expression in NCI/ADR
Res
 
cells (Fig. 7b). 
The effects of both drugs on cellular levels of the essential membrane protein Na/K-ATPase were 
also investigated. ZSTK474 caused a significant, time-dependent reduction in expression of the 
Na/K-ATPase in both NCI/ADR
Res
 (Fig. 7c) and MCF7
WT
 cells (Fig. 7e). Nicardipine, however, did 
not cause any change in Na/K-ATPase levels in NCI/ADR
Res
 cells (Fig. 7d). The data with the 
Na/K-ATPase suggests that ZSTK474 may have a general effect on cellular protein levels. 
Since ABCB1 is degraded through the proteasomal pathway, the effects of ZSTK474 on ABCB1 
expression were assessed in the presence, and absence, of the proteasome inhibitor Bortezomib. As 
shown in Fig. 9a, expression of ABCB1 reached plateau on day 4 at which time ZSTK474 (1mM) 
was added (marked with arrow). The 2-day incubation with ZSTK474 was sufficient to reduce 
ABCB1 levels (10,780±760 vs 15,930±3377 pixels). On the other hand, bortezomib had no 
significant effect on ABCB1 levels (Fig. 9b). However, the co-administration of bortezomib and 
ZSTK474 led to diminution of ABCB1 expression (2466±601 vs 15930±3377 pixels) at day 6 (Fig. 
9c). The lack of any stabilisation of ABCB1 levels during co-addition with bortezomib suggests that 
ZSTK474 does not influence ABCB1 levels by enhancing its proteasomal degradation. In addition, 
the inability of bortezomib treatment to increase ABCB1 expression may be related to the ability of 
this pump to mediate efflux of the proteasomal inhibitor (O'Connor et al., 2013). 
Altered transcription provides an alternative mechanism for ZSTK474 to modulate ABCB1 
expression. Consequently, ABCB1 mRNA levels were measured using qRT-PCR and related to the 
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house-keeping gene GAPDH, whose mRNA levels were unaffected by ZSTK474 (1mM). ABCB1 
mRNA levels at 24-hour post-seeding, obtained in the absence of ZSTK474, were normalised to a 
value of 1.0 (Fig. 10a). In the subsequent 72-hour period, cells were incubated with ZSTK474 
(1mM) and ABCB1 mRNA levels measured every 24-hours. As shown in Fig. 10a, the addition of 
ZSTK474 to the NCI/ADR
Res
 cells did not alter ABCB1 mRNA levels over 72-hours. This suggests 
that the observed reduction in ABCB1 expression by ZSTK474 was unlikely to have occurred 
through altered transcription.  
Steady-state levels of proteins also depend on the rate of de novo synthesis. Consequently, the 
effects of ZSTK474 on total cellular protein synthesis were measured using a fluorescent assay 
involving O-propargyl-puromycin (OPP), which incorporates into the C-terminus of nascent 
polypeptide and halts translation. OPP contains an alkyne moiety that reacts with the carboxy-
fluorescein containing FAM-azide; thereby enabling its detection by fluorescence spectroscopy. 
Fig. 11 shows the effects of ZSTK474 or cycloheximide on total protein synthesis. The translation 
inhibitor cycloheximide (100mg/ml) was used as a positive control as shown by reduction in de 
novo protein synthesis in the MCF7
WT
 cells to 42±8% and to 53±10% in the NCI/ADR
Res
 cells. At 
3mM, ZSTK474 reduced overall protein synthesis in the NCI/ADR
Res
 cells to 62±5% (P<0.05) of 
the untreated sample and to 49±5% (P<0.05) in the MCF7
WT
 cells. At both concentrations 
investigated, ZSTK474 caused a significant reduction in overall protein synthesis in drug sensitive 
and resistant cells. This reduction in overall cellular protein synthesis may result in lower levels of 
ABCB1 in NCI/ADR
Res
 cells and also account for reduced levels of Na/K-ATPase in both cell lines. 
 
3.7 The effects of ZSTK474 on the levels of ABCG2 in cancer cell lines 
During a 6-day growth period, levels of ABCG2 reached a plateau approximately 2-3 days post-
seeding of MCF7
FLV1000
 cells (Fig. 8a). In the presence of ZSTK474 (1mM), the levels of ABCG2 
were similar to the vehicle control for the first 48 hours. However, the levels of ABCG2 decreased 
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dramatically (5196±899 vs 14285±2976 pixels) by day 6 in the presence of ZSTK474 (Fig. 8a). In 
contrast, the ABCG2 inhibitor FTC (1mM) had no appreciable effect on ABCG2 levels in 
MCF7
FLV1000
 cells (Fig. 8b). Therefore, the reduction in ABCG2 expression caused by ZSTK474 
was not simply related to prolonged inhibition of ABCG2 function. 
The effects of ZSTK474 on Na/K-ATPase levels were also measured over the 6-day growth period 
in MCF7
FLV1000
 cells (Fig. 8c). The addition of ZSTK474 (1mM) resulted in reduced levels of Na/K-
ATPase in the cells, suggesting a general effect on cellular proteins. In contrast, addition of FTC 
(1mM) did not cause any alteration in Na/K-ATPase levels in MCF7
FLV1000
 cells.  
The primary cellular degradation pathway for ABCG2 is lysosomal. ZSTK474 (1mM) produced a 
reduction in ABCG2 levels compared to the vehicle control in MCF7
FLV1000
 cells (Fig. 9d). In 
contrast, the lysosomal inhibitor concanamycin A had no appreciable effect on ABCG2 levels (Fig. 
9e). However, the combination of ZSTK474 and concanamycin A produced an increase in ABCG2 
levels (Fig. 9f). The ability of concanamycin A to prevent the ZSTK474-mediated reduction in 
ABCG2 expression suggests an involvement of the lysosomal degradation route. 
The possibility that ZSTK474 alters ABCG2 levels by reducing transcription was also investigated 
using a similar treatment strategy to that described for ABCB1 (Fig. 10b). Incubation (24-96 h) of 
MCF7
FLV1000
 cells with ZSTK474 (1mM) did not cause a statistically significant alteration in 
ABCG2 mRNA levels, indicating that transcription was unaffected. 
The effects of ZSTK474 on protein translation in cells expressing ABCG2 were also undertaken 
using the OPP-based fluorescent assay and the results are shown in Fig. 11. Addition of ZSTK474 
(1mM) was associated with reduced protein translation to 66±8 % (P<0.05) compared to untreated 
MCF7
FLV1000
 cells. Increasing the concentration of ZSTK474 to 3mM did not produce any further 
reduction, with protein translation maintained at 67±4% of control. This decrease in the de novo 
protein synthesis by ZSTK474 accounts for the reduction in ABCG2 levels in the MCF7
FLV1000
 cell 
line. 
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4. Discussion 
The majority of compounds developed to circumvent ABCB1 or ABCG2 mediated resistance are 
classified as “inhibitors” that prevent drug efflux and restore anticancer drug accumulation to levels 
that inhibit cell proliferation. Despite success in vitro, this has failed to translate into clinical usage 
and alternative strategies are clearly required. The PI3K inhibitor ZSTK474 offers numerous 
advantages over previously described ABCB1/ABCG2 inhibitors. Specifically, this investigation 
has shown that ZSTK474 (i) inhibits drug transport by ABCB1 and ABCG2, (ii) reduces levels of 
the pumps and (iii) possesses inherent anti-proliferative activity. 
The anti-proliferative activity of ZSTK474 has also been demonstrated in numerous cell lines and 
xenograft models (Yaguchi et al., 2006; Zhou et al., 2016), resulting in cell cycle arrest in G1-phase 
(Kong and Yamori, 2008). Cell cycle arrest is related to modulating the PI3K/Akt signalling 
pathway. In the present investigation, the growth inhibitory effects of ZSTK474 in breast cancer 
cells were unaffected by the presence of ABCB1 or ABCG2. Moreover, the growth arrest by 
ZSTK474 was synergistic when co-administered with vinblastine in cells expressing ABCB1. This 
synergy may be related to the cellular target of vinblastine, which is a disruptor of microtubule mass 
and dynamics. Synergy also exists between ZSTK474 and the Bcr-Abl inhibitor Imatinib in the 
chronic myelogenous leukaemia (CML) cell line K562 (Zhou et al., 2016). Co-administration of 
ZSTK474 also improved the cytotoxic potency of Imatinib in the drug resistant variant K562/A02, 
which over-expresses ABCB1. The authors concluded that ZSTK474 was able to “overcome” the 
ABCB1 mediated resistance against Imatinib. It is possible that ZSTK474 may either inhibit 
ABCB1, or that it “competes” for transport out of the cells with vinblastine and thereby exhibits 
synergistic activity. 
An analogous situation was observed in resistant cells that over-express ABCG2 where the addition 
of ZSTK474 potentiated the cytotoxicity of mitoxantrone; in this case the interaction was additive. 
This potentiation agrees with an earlier investigation demonstrating that the PI3K/Akt inhibitor 
24 
 
LY294002 could also overcome the resistance phenotype conferred by ABCG2 to the 
topoisomerase-I inhibitors SN-38 and topotecan (Imai et al., 2012). Moreover, ABCG2 did not 
confer resistance to LY294002 per se. In contrast, ABCG2 was able to confer resistance to another 
PI3K inhibitor CUDC-907 by reducing its intracellular accumulation (Wu et al., 2016). In the 
present investigation, ABCG2 over-expression did not lead to resistance of cells to the anti-
proliferative activity of ZSTK474, which suggests that it is not a substrate for transport by this 
pump. In addition, a recent study has shown that exposure of cells to ZSTK474 for over a year 
failed to generate elevated levels of ABCG2 (Isoyama et al., 2012). 
The observation that the anti-proliferative activity of ZSTK474 is unaffected by the presence of 
ABCB1, or ABCG2, does not preclude a direct interaction between ZSTK474 and either pump. The 
addition of ZSTK474 rapidly produced an increase in the accumulation of calcein-AM in ABCB1 
expressing cells. The rapidity of this effect suggests a direct action on the transport process. In the 
case of ABCG2, ZSTK474 also inhibited transport of mitoxantrone with similar potency to the 
ABCG2-selective inhibitor FTC and over a comparable timeframe. A direct interaction has been 
reported for another PI3K inhibitor, LY294002 (Pick and Wiese, 2012). Therefore it appears that 
ZSTK474, whilst not a substrate for transport by the pumps, is able to overcome the drug resistant 
phenotype conferred by ABCB1 or ABCG2 via direct inhibition of their transport activity. 
Corroborating evidence of a direct ZSTK474-protein interaction was obtained using purified 
reconstituted ABCB1. The rate of ATP hydrolysis by ABCB1 was stimulated by ZSTK474 to a 
similar extent and potency to that observed for the inhibitor nicardipine. Numerous studies have 
demonstrated that the direct binding of inhibitors and substrates to ABCB1 produce altered rates of 
ATP hydrolysis (Wang et al., 2012). For example, the inhibitor Tariquidar reduces the rate of ATP 
hydrolysis, whereas inhibitors such as nicardipine are associated with stimulatory effects (Zhang et 
al., 2008). It has been postulated that inhibitors of transport may actually stimulate ATP hydrolysis 
by uncoupling drug binding from nucleotide hydrolysis during translocation (Nair and Cheson, 
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2016). Data from the present investigation indicates that ZSTK474 can directly interact with 
ABCB1 and this interaction is likely responsible for the reduction in calcein-AM efflux.  
ZSTK474 has been predicted by molecular modelling to bind within the ATP-binding pocket of 
PI3K to produce inhibition of kinase activity (Yaguchi et al., 2006). However, it is unlikely to 
interact within the Nucleotide Binding Domains (NBDs) of ABCB1, which provide energy for 
transport. The primary reason was the observation that ZSTK474 stimulates the rate of ATP 
hydrolysis by ABCB1. It is established that ABCB1 requires two fully functional NBDs to carry-
out ATP hydrolysis and subsequent drug translocation (Urbatsch et al., 1995). Binding of the 
compound to either, or both, NBDs would preclude ATP hydrolysis by ABCB1 and therefore, 
ZSTK474 is more likely to exert its effect by interaction at the poly-specific drug binding cavity in 
the transmembrane domain. 
It is possible that inhibition of the PI3K/Akt signalling pathway by ZSTK474 may also influence 
the resistance conferred by ABCB1 or ABCG2 via indirect effects. Both 3-methyl-adenine (Zou et 
al., 2014) and the Traditional Chinese Medicine formulation Zuo Jin Wan (Sui et al., 2014) have 
been shown to restore anticancer drug potency in cells expressing ABCB1 by inhibiting the 
PI3K/Akt/mTOR pathway. Similarly, siRNA and pharmacological approaches to inhibiting 
PI3K/Akt signalling have resulted in reduced levels of ABCG2 and restoration of anticancer drug 
sensitivity (Komeili-Movahhed et al., 2015; Takada et al., 2005). These reports implicate the 
PI3K/Akt pathway in regulating the resistance phenotype conferred by these efflux pumps with an 
indirect mechanism, such as a reduction in their expression. 
In the present investigation, ZSTK474 also caused a significant reduction in the expression of 
ABCB1 in the NCI/ADR
Res
 cells. This did not occur through transcriptional regulation since the 
levels of mRNA for ABCB1 were unaltered by drug. Furthermore, ZSTK474 did not enhance 
ABCB1 degradation since inhibition of the proteasome by bortezomib would have been anticipated 
to elevate ABCB1 levels. Strikingly, co-administration of bortezomib with ZSTK474 produced a 
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synergistic reduction in ABCB1 levels. This may be explained by a bortezomib mediated reduction 
in ABCB1 expression in certain cell lines by modulating the NF-kB pathway (Wang et al., 2012). 
Another widely used proteasome inhibitor, MG-1302, also causes a reduction in ABCB1 expression 
via interaction with Bcl-2 (Zhang et al., 2008). These observations render attribution of a 
proteasomal mechanism to the ZSTK474-mediated reduction in ABCB1 expression problematic. 
ZSTK474 also caused a marked reduction in ABCG2 levels in MCF7
FLV1000
 cells. Unlike ABCB1, 
the degradation of ABCG2 occurs through the lysosomal pathway (Wakabayashi et al., 2007). 
Several xanthines have been shown to reduce expression of ABCG2, and overcome chemo-
resistance, by enhancing its degradation in the lysosome (Ding et al., 2012). However, the co-
addition of ZSTK474 with the lysosomal inhibitor concanamycin A resulted in only minor elevation 
of ABCG2 expression. This suggests that the ZSTK474 uses an alternative pathway to reduce levels 
of ABCG2. 
The observation that ZSTK474 also caused reduced levels of Na
+
/K
+
-ATPase in drug sensitive and 
resistant cells offered the possibility of a more generic effect. This idea was supported by the large 
decrease in the overall cellular rate of protein translation caused by ZSTK474 in all three cell lines. 
The PI3K/Akt signalling pathway has myriad cellular effects with altered protein expression 
typically occurring through the route involving mTOR (Bauer et al., 2015; Kong and Yamori, 
2008). Moreover, it has been shown in neuronal tissue that ZSTK474 leads to specific inhibition of 
the mTORC1 pathway (Wang et al., 2016b), which is normally involved in the activation of protein 
translation processes. Inhibition of the Akt/mTOR signalling pathway by compounds such as 
resveratrol will lead to decreased protein synthesis, including ABCB1 as shown in drug resistant 
K562/ADR cells (Wang et al., 2016a). Furthermore, the resveratrol-mediated reduction in ABCB1 
expression restored the sensitivity of K562/ADR cells to the anti-proliferative di-peptide Bestatin. 
Similarly, blocking the PI3K/Akt/mTOR signalling pathway by 3-methyl-adenine has been shown 
to reduce levels of ABCG2 and sensitise cells to a variety of anticancer drugs (Zou et al., 2014). 
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Together these observations support the conclusion that inactivation of the PI3K/Akt/mTOR 
pathway by ZSTK474 has an indirect effect on the resistant phenotype, namely, the reduction in 
ABCB1 and ABCG2 through inhibition of overall protein translation. 
Conclusions: We have shown that the PI3K inhibitor ZSTK474 causes multiple effects on drug 
resistant cancer cells that over-express the efflux pumps ABCB1 and ABCG2. ZSTK474 causes 
growth inhibition in resistant and sensitive cells with similar potency, suggesting that its 
accumulation is relatively unaffected by these two pumps. Nonetheless, ZSTK474 can restore 
anticancer drug efficacy in resistant cell lines, which was achieved by directly inhibiting the drug 
transport activity of the pumps. ZSTK474 also facilitated the activity of anticancer drugs by 
reducing levels of ABCB1 or ABCG2 through a post-transcriptional mechanism. Therefore, 
ZSTK474 offers a novel multi-pronged strategy to restore anticancer drug efficacy in cells 
expressing ABCB1 or ABCG2. These observations warrant further investigation into combination 
therapy, particularly in tumours exhibiting over-expression of these multidrug efflux pumps. 
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Figure Legends 
 
Figure 1 Cytotoxicity of ZSTK474 in cells over-expressing ABCB1 and ABCG2 
MCF7
WT
 (l), NCI/ADRRes (m) and MCF7FLV1000 (n) cells were grown in the presence of 
ZSTK474 (10
-12
 to 10
-4 
M) for seven days. The percentage of viable cells remaining after this time 
was determined using an MTT assay. The data shown as mean±S.E.M was fitted by the general 
dose-response relationship using non-linear regression and was obtained from a minimum of three 
independent observations. 
 
Figure 2 Potentiation of anticancer drug cytotoxicity by ZSTK474 in cells expressing 
ABCB1 or ABCG2 
Cell cytotoxicity was determined for anticancer drugs in the presence of varying concentrations 
ZSTK474 (none l; 0.1mM n; 0.3mM p; 1mM q; 3mM u) for seven days. Dose response curves 
were generated in MCF7
WT
 (a) and NCI/ADR
Res
 cells (c) using vinblastine (10
-11
 to 10
-4
 M). 
Mitoxantrone (10
-11
 to 10
-3
 M) was used in MCF7
WT
 (b) and MCF7
FLV1000
 (d) cells. The data was 
fitted by the general dose-response relationship using non-linear regression. Secondary plots were 
generated to show the extent of cell death obtained at a 10
-11
 M concentration of vinblastine (e) or 
mitoxantrone (f) in the presence of varying ZSTK474 concentrations for sensitive (filled bars) and 
resistant cells (clear bars). All data represent the mean±S.E.M obtained from a minimum of three 
independent observations. 
 
Figure 3 Isobologram analyses of cytotoxicity profiles of vinblastine/ZSTK474 and 
mitoxantrone/ZSTK474 combinations in MCF7
WT
, NCI/ADR
Res
 and MCF7
FLV1000
 cells 
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Combination Index values for the vinblastine/ZSTK474 combination in (a) MCF7
WT
 and (b) 
NCI/ADR
Res
 cells were determined from IC75 values. Combination Index values for the 
mitoxantrone/ZSTK474 combination in (c) MCF7
WT
 and (d) MCF7
FLV1000
 cells were calculated at 
50% cell death (IC50). The line of additivity is shown as a dotted line; points below the dotted line 
indicate synergy, points on the line indicate an additive effect and points above the line indicate 
antagonism. Values shown are the average ± S.E.M from ≥3 independent experiments. 
 
Figure 4 The effects of ZSTK474 and nicardipine on calcein-AM accumulation in cells 
over-expressing ABCB1 
MCF7
WT
 and NCI/ADR
Res
 cells were grown to confluency in 96-well plates and calcein-AM (2mM) 
was added in the presence or absence of drug. Fluorescence was measured for a period of 10 
minutes following the addition of calcein-AM and the rate determined from the slope of the change 
in fluorescence. The rate of calcein-AM accumulation was plotted as a function of either (a) 
nicardipine or (b) ZSTK474 and fitted, by non-linear regression, with a hyperbolic function. Data 
represents the mean±S.E.M obtained from at least three independent observations. 
 
Figure 5 Stimulation of the ATPase activity of purified, reconstituted P-gp by ZSTK474 
Purified, reconstituted P-gp was incubated in the presence of a fixed concentration of ATP (2mM) 
and varying concentrations of ZSTK474. The samples were incubated at 37
o
C for 40 minutes and 
the amount of inorganic phosphate liberated was determined using a colorimetric assay. ATPase 
activity was normalised for protein amount and plotted as a function of ZSTK474 concentration. 
The general dose-response relationship was fitted using non-linear regression and the data 
represents the mean±S.E.M obtained from four independent observations. 
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Figure 6 The effects of ZSTK474 on mitoxantrone accumulation in cells over-expressing 
ABCG2 
The effect of ZSTK474 on the transport process of ABCG2 was measured using a flow cytometry 
assay. MCF7
WT
 and MCF7
FLV1000
 cells were incubated for an hour with mitoxantrone (3mM) in the 
presence or absence of varying concentrations of ZSTK474 and the intracellular accumulation of 
mitoxantrone was detected using a BD LSR II flow cytometer equipped with a red 633 nm laser. 
(a) Cell count was plotted as a function of the average mitoxantrone accumulation in MCF7
WT
 cells 
(red solid line), MCF7
FLV1000
 cells (blue solid line) and MCF7
FLV1000
 cells in the presence of 10mM 
ZSTK474 (dotted blue line).  
(b) A histogram was generated for mitoxantrone accumulation in MCF7
WT
 (clear bars) and 
MCF7
FLV1000
 (solid bars) cells the presence of increasing ZSTK474 concentrations. Data represents 
the mean±S.E.M obtained from at least three independent observations. * indicates a statistically 
significant (P<0.05) difference from the value obtained in MCF7
FLV1000
 cells in the absence of 
ZSTK474. 
 
Figure 7 Effects of ZSTK474 and nicardipine on ABCB1 and Na/K-ATPase levels in 
NCI/ADR
Res
 cells 
MCF7
WT
 and NCI/ADR
Res
 cells were incubated withZSTK474 (1mM) or nicardipine (1mM) for up 
to 6 days. Lysates were prepared in 1% (w/v) SDS and the total protein concentration was 
determined for each sample. The expression of ABCB1 (140kD band) was detected using the C219 
monoclonal antibody and the Na/K-ATPase a-subunit (100kD band) detected with the C464.6 
monoclonal antibody. Each panel provides a representative vehicle control (DMSO) and the drug 
treatment. ABCB1 expression in NCI/ADR
Res
 cells was shown in panels (a) and (b) following 
treatment with ZSTK474 and nicardipine, respectively. Na/K-ATPase levels in NCI/ADR
Res
 cells 
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are shown in panels (c) and (d) following treatment with ZSTK474 and nicardipine respectively. 
Panel (e) shows the expression of Na/K-ATPase in the absence or presence of ZSTK474 in 
MCF7
WT
 cells. Normalisation of the 8% SDS-PAGE gels was achieved quantitatively by loading 
9mg of total cellular protein in each lane.  
 
Figure 8 Effect of ZSTK474 and FTC on ABCG2 and Na/K-ATPase levels in MCF7
FLV1000
 
cells 
ZSTK474 (1mM) or FTC (1mM) were added to MCF7
WT
 and MCF7
FLV1000
 cells for a period of 6 
days. Lysates were prepared in 1% (w/v) SDS, the protein concentration was determined and 9mg of 
total cellular protein in each lane of an 8% SDS-PAGE gel. The expression of ABCG2 was detected 
(72kD band) using the BXP-21 monoclonal antibody and the Na/K-ATPase a-subunit (100kD 
band) with the monoclonal antibody C464.6. The blot in each panel consists of samples obtained 
from either a vehicle control (DMSO) or the drug treatment. ABCG2 levels in MCF7
FLV1000
 cells 
are shown in panels (a) and (b) following treatment with ZSTK474 and FTC respectively. Na/K-
ATPase levels in MCF7
FLV1000
 cells are shown in panels (c) and (d) following treatment with 
ZSTK474 and FTC, respectively. 
 
Figure 9 Effects of ZSTK474 and protein degradation pathway inhibitors on ABCB1 and 
ABCG2 
ZSTK474 was added to drug cells alone or in combination with inhibitors of protein degradation. 
Drugs, inhibitors or vehicle (DMSO) were added at day four (é), when ABCB1 or ABGC2 
expression reached steady-state and left for a further two days. Lysates were prepared in 1% (w/v) 
SDS, the total protein concentration was determined for each sample and 9mg loaded in each lane. 
ABCB1 (140kD band) was detected in NCI/ADR
Res
 cells (NCI) using the monoclonal antibody 
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C219 and ABCG2 (72kD band) was detected in MCF7
FLV1000
 cells (FLV) using the monoclonal 
antibody BXP-21. Bortezomib (BZ) (10nM) was used to inhibit proteasomal degradation and 
concanamycin A (ConA) (50nM) was used to inhibit lysosomal protein degradation. 
 
Figure 10 Effects of ZSTK474 on ABCB1 and ABCG2 mRNA levels 
NCI/ADR
Res
 (a) or MCF7
FLV1000
 cells (b) were treated with ZSTK474 (1mM) for four days. Samples 
were collected every 24 hours and mRNA levels for the two transporters measured by qRT-PCR. 
ABCB1 and ABCG2 mRNA levels were normalised relative to GAPDH. The latter was assigned a 
value of 1.0 and the data represent the mean±S.E.M obtained from three independent observations. 
 
Figure 11 The effects of ZSTK474 on de novo protein synthesis in MCF7
WT
, NCI/ADR
Res
 and 
MCF7
FLV1000
 cells 
MCF7
WT
 and NCI/ADR
RES
 cells were incubated in the presence or absence of ZSTK474 or 
cyclohexamide for 24 hours. In the MCF7
FLV1000
 cell line, the incubation with ZSTK474 was 
extended to 48 hours. Total de novo protein synthesis was measured using a fluorescence based 
assay that detects incorporation of a puromycin analogue OPP. The clear, black and hashed bars 
represent relative protein synthesis in MCF7
WT
, NCI/ADR
RES
 and MCF7
FLV1000
 cells, respectively. 
Values were normalised relative to the no drug control, which was set to an arbitrary value of 
100%. Data shown were obtained from at least three independent observations. * indicates a 
statistically significant (P<0.05) difference compared to the value obtained for each cell line in the 
absence of added drug using one way ANOVA. 
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